CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances<i>In vivo</i>Persistence and Antitumor Efficacy of Adoptively Transferred T Cells
Claudia Kowolik, Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center), Stephen J. Forman(City Of Hope National Medical Center), Simon Olivares, David Smith(City Of Hope National Medical Center), Timothy Pfeiffer, Max S. Topp(Universitätsklinikum Würzburg), Sergio González, Nancy González, Michael C. Jensen(Seattle Children's Hospital)
Cited by 487
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754